• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

    30.69 +0.01 (+0.03%)
    Streaming Delayed Price Updated: 12:47 PM EDT, May 22, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Viking Therapeutics, Inc. - Common Stock

    Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities
    Via Investor Brand Network
    InvestorNewsBreaks – SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Featured in BioMedWire Editorial on Next-Generation GLP-1 Innovation
    Via Investor Brand Network
    News headline image
    The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
    From stem cell therapies for frailty to α-Klotho protein programs and GLP-1 drug classes now labeled "longevity therapeutics," the science and the capital have finally met 
    From Equity Insider
    Via GlobeNewswire
    News headline image
    Market Brief: After Viking Therapeutics’ Results, Is Entera Bio the Oral Platform Play to Watch? (NASDAQ: ENTX)
    Via AB Newswire
    Viking Therapeutics Inc. (NASDAQ: VKTX) is a Stock Spotlight on 5/23
    Via Investor Brand Network
    News headline image
    Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities
    From BioMedWire
    Via GlobeNewswire
    News headline image
    Profusa Inc (NASDAQ: PFSA) Establishes a distributor partner in Spain for Lumee Oxygen platform
    Via AB Newswire
    News headline image
    Is Viking Therapeutics Ready For Another Surge?
    Viking Therapeutics' promising weight loss drug could revolutionize the obesity market and propel the company's stock price to new highs. 
    Via MarketBeat
    News headline image
    Viking Therapeutics Is Having a Year to Remember: Time to Buy?
    Viking Therapeutics Inc. (NASDAQ: VKTX) has surged 238% year-to-date and 326% over the past year, far outpacing its sector and market. 
    Via MarketBeat
    News headline image
    Viking Therapeutics: Pharma Stock Soars on Positive Earnings
    Viking Therapeutics stock soars on clinical trial results and a solid earnings beat, signaling a potential market shake-up in the biopharmaceutical sector. 
    Via MarketBeat
    Topics Earnings
    News headline image
    Eli Lilly Stock Leads in GLP-1 Race with its Triple Agonist Drug
    Global pharmaceutical company Eli Lilly & Co. (NYSE: LLY) has been in a GLP-1 arms race with its FDA-approved therapies Mounjaro and Zepbound. It's been 
    Via MarketBeat
    News headline image
    Altimmune Stock: Is Its GLP-1 Drug the Next Ozempic Killer?
    Clinical-state biopharmaceutical company Altimmune Inc. (NASDAQ: ALT) focuses on developing peptide-based therapeutics for obesity and chronic liver diseases 
    Via MarketBeat
    News headline image
    Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes
    Pharmaceutical giant Pfizer Inc. (NYSE: PFE) has been trying to enter the weight-loss treatment trend dominated by GLP-1 drug makers like Ozempic and Wegovy 
    Via MarketBeat
    News headline image
    Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
    Global pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) has made headlines with its leading GLP-1 weight loss drugs, Mounjaro and Zepbound. 
    Via MarketBeat
    News headline image
    Eli Lilly Gains on the GLP-1 Weight Loss Phenomenon
    Eli Lilly stock continues to move higher after the company reported continuing momentum for its flagship GLP-1 weight loss drugs 
    Via MarketBeat
    News headline image
    Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
    The GLP-1 weight loss trend continues to flourish, and the ante keeps rising; see how the winner between Wegovy and Zepbound can help your portfolio 
    Via MarketBeat
    News headline image
    Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out?
    Altimmune has a GLP-1 candidate in Phase 2 trials, but the company continues to burn cash and may need a big pharma partner to get its drug to market 
    Via MarketBeat
    News headline image
    MarketBeat Week in Review – 4/1 - 4/5
    Equities lost ground this week as investors consider the effect of fewer rate cuts, rising oil prices, and robust job gains ahead of a new earnings season 
    Via MarketBeat
    Topics Economy
    News headline image
    Viking Therapeutics Surges Sentiment for Triple Threat GLP-1Pill
    Viking Therapeutics is preparing to be the next entry into the GLP-1 Market, and VKTX stock is soaring as analysts start to bid the stock higher 
    Via MarketBeat
    News headline image
    7 Stocks That Will Drive the Weight Loss Drugs Market
    The booming weight loss drug market presents both lucrative potential and significant risks for investors seeking to capitalize on the global obesity crisis. 
    Via MarketBeat
    News headline image
    Vivani Medical Surges on its Ozempic-Like Weight-Loss Implant
    The Ozempic craze continues to make headlines in the medical sector, and GLP-1 drug stocks such as Vivani Medical continue to surge higher 
    Via MarketBeat
    Viking Therapeutics Inc. (NASDAQ: VKTX) Near Top of Volume Charts in Tuesday Trading
    Via Investor Brand Network
    News headline image
    2 biotechs with promising weight-loss drugs coming
    Clinical weight-loss medications have been making headlines as GLP-1 drugs like Novo Nordisk A/S (NYSE: NVO) owned Ozempic and Wegovy and Eli Lilly and Co. 
    Via MarketBeat
    Melanocortin Receptor R&D to Target Increasing Prevalence of Obesity-Related Disorders
    EQNX::TICKER_START (NYSE:PTN),(NASDAQ:RYTM),(NASDAQ:VKTX),(NASDAQ:GPCR),(NYSE:NVO) EQNX::TICKER_END 
    Via FinancialNewsMedia
    News headline image
    Lilly Shares Up On Versanis Deal Amid Weight-Loss Drug Gold Rush
    A bid to acquire Versanis boosts Eli Lilly & Co. by 2.80% in the past week, as the competition to develop the most effective weight-loss drug intensifies. 
    Via MarketBeat
    News headline image
    Here are 2 Top Drug Makers Leading the Way in Weight Loss Drugs
    The topic of weight loss drugs has been making recent headlines. The positive phase 1 clinical trial for Viking Therapeutics Inc. (NASDAQ: VKTX) GLP-1 treatme 
    Via MarketBeat
    Viking Therapeutics Inc. (NASDAQ: VKTX) Records 52-Week High Tuesday Morning
    Via Investor Brand Network
    News headline image
    Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
    Clinical-stage biotechnology company Viking Therapeutics, Inc. (NASDAQ: VKTX) stock jumped more than 50% on positive Phase 1 data on its novel dual GLP-1/GLP 
    Via MarketBeat
    News headline image
    Why Did Viking Therapeutics Stock Skyrocket
    VKTX stock is young but strong and they have excellent potential, particularly following successful trial results from Madrigal Pharma's recent drug trial. 
    Via MarketBeat
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.